On June 25th, the Fourth China Biomedical Innovation Cooperation Conference came to a successful conclusion. Mr. Mao Hua, Partner and Managing Director of Frost & Sullivan's Greater China Region, was invited to attend the event and deliver a keynote speech, sharing his professional insights on the cell and gene therapy industries.
Mao Hua said that with the increasing maturity of medical technology and related regulations, the global CGT treatment market has entered a golden age. In contrast, China's CGT treatment market is still in its infancy. Recent continuous technological breakthroughs have brought prosperity to CGT. However, the number of approved CGT products in China is still lower than that in Europe and America, leaving significant room for exploration in the future.
"The globally ongoing CGT clinical trials have expanded into diverse disease areas, currently covering genetic diseases, malignant tumors, infectious diseases, and chronic diseases. Domestic clinical trials in China are more focused on tumor treatment, with significant potential for expanding indications in the future." He analyzed that under the global trend of rapid growth in the market size of gene therapy, the market size of gene therapy in China will also expand rapidly due to favorable policies and increased R&D investment. Among them, CAR-T therapy has huge market potential in the future.
At the meeting, Mao Hua also introduced to the attendees the latest research findings of Frost & Sullivan - the 'White Paper on the Development of China's Cell and Gene Therapy Industry'. Based on Frost & Sullivan's ongoing in-depth research into the Chinese CGT industry market, this white paper aims to provide important reference perspectives for CGT market investors. Previously, Frost & Sullivan has published several industry development white papers including the 'White Paper on the Development of China's Pharmaceutical CXO Industry' and the '2021 White Paper on the Promotion of Health Management through Health Insurance in China', covering many sub-fields of the healthcare industry.
In the future, Frost & Sullivan will continue to keep track of the latest developments in the biopharmaceutical and healthcare industries, continuously producing its own industry observations and perspectives. He revealed: 'Currently, white papers on the development of oncolytic virus industries, small molecule targeted drug industries, IVD in vitro diagnostic industries, neuro and peripheral interventional industries, and surgical robot industries are all in the preparation stage and will be released to the market gradually thereafter. We welcome everyone's continued attention.'
